Recent medical studies have shown that Zofran taken by pregnant women can cause intrauterine growth restriction (IUGR), a condition when an unborn baby weighs less than 90% of other infants at the same gestational age. The drug has been prescribed to women during the first trimester of pregnancy to control nausea. The drug company failed to warn physicians and mothers about the possible birth defects associated with taking Zofran during pregnancy.

Intrauterine growth restriction is typically defined as a fetal weight below the tenth percentile for gestational age. It is also referred to as small-for-gestational age (SGA) or fetal growth restriction. There are two main types of IUGR:

  • Symmetric or Primary IUGR – Characterized by a reduction in size of all internal organs. This form of the defect accounts for approximately 20% to 25% of all cases of intrauterine growth restriction.
  • Asymmetric or Secondary IUGR – Head and brain are normal in size, but the abdomen is smaller. This form of intrauterine growth restriction is typically not observable until the 3rd trimester of pregnancy.

IUGR Symptoms

Signs and symptoms of intrauterine growth restriction may include:

  • Low birth weight
  • Difficulty handling delivery
  • Decreased oxygen levels
  • Low blood sugar (hypoglycemia)
  • Low resistance to infection
  • Low Apgar scores
  • Trouble maintaining body temperature
  • High red blood cell count

Treatment for IUGR depends on a number of factors, including how far along the mother is in her pregnancy. Many times, close monitoring is necessary and immediate delivery by C-section can be required to prevent further harm to the baby. The child may suffer long term problems from this condition.

Zofran IUGR Lawsuits

Lawsuits are being filed against the drug manufacturer by parents of children with IUGR when the mother took this medication during pregnancy. The settlements in these cases are expected to be significant. Our Zofran attorneys can help you and your child with your case.

To get started on your Zofran IUGR claim, you can call us anytime at (866) 280-4722 or submit the Free Case Review Box on this page. We will contact you to learn more about your case and explain how we can help you. There are absolutely no legal fees or costs unless you receive a settlement.

  • Was this information helpful?
  • Yes   No

View Sources

  1. Hernandez-Rodriguez J1, Meneses L, Herrera R, Manjarrez G. Another abnormal trait in the serotonin metabolism path in intrauterine growth-restricted infants. Neonatology. 2009;95(2):125-31. doi: 10.1159/000153096. Epub 2008 Sep 6. http://www.ncbi.nlm.nih.gov/pubmed/18776726
  2. A Jensen, HJ Klonne, A Detmer and AM Carter. Catecholamine and serotonin concentrations in fetal guinea-pig brain: relation to regional cerebral blood flow and oxygen delivery in the growth-restricted fetus. Reproduction, Fertility and Development. 1996; 8(3) 355 – 364. http://www.publish.csiro.au/paper/RD9960355.htm
  3. Chrzanowska B, Wenzel E, Prokopczyk J. [Serotonin concentration in the placentas in experimental intrauterine growth retardation]. Probl Med Wieku Rozwoj. 1981;10:233-6. [Article in Polish] http://www.ncbi.nlm.nih.gov/pubmed/7349398
  4. Siu SS1, Chan MT, Lau TK. Placental transfer of ondansetron during early human pregnancy. Clin Pharmacokinet. 2006;45(4):419-23. http://www.ncbi.nlm.nih.gov/pubmed/16584287